



\*\*\*\*Published January 2020\*\*\*

## MarketVIEW: Middle East Respiratory Syndrome (MERS-CoV) vaccines (CAT: VAMV082)

<b>Product Name</b>	:	<b>MarketVIEW: Middle East Respiratory Syndrome (MERS-CoV) vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment
<b>Contents</b>	:	Executive presentation (~154 slides.pdf) + MS-Excel forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>Novel pandemic/CEPI vaccines</b>
<b>Publication date</b>	:	January 2020
<b>Catalogue No</b>	:	VAMV082

## Background

MERS-CoV, a novel coronavirus causes **Middle East Respiratory Syndrome** a new disease first identified in Saudi Arabia in 2012. MERS has become significant because it is a virus considered by the WHO and other organisations, e.g. CEPI Coalition for Epidemic Preparedness Innovations to have pandemic potential. At the end of November 2019, 2494 cases of MERS had been reported across 27 countries, but importantly 858 persons had died (case fatality rate = 34.4%). Although transmission is mainly from animals to people, MERS has on occasion been transmitted from human to human, heightening concern. For example, in 2015 MERS infected 185 people starting from an index case that had travelled from the Middle East.

MERS has no specific treatment, but efforts to develop a preventative vaccine are underway. Three main candidates using a range of vaccine technologies are now in clinical studies being pursued by various consortiums that involve both the public and private sectors. For example, large companies such as Janssen Vaccines are supporting ChAdOx1 MERS a single dose Replication-deficient simian adenovirus vector, containing the MERS Spike protein antigen (Phase I/Ib).

This **MarketVIEW** product is a comprehensive Executive Presentation (~100 slides) and MS-Excel forecast model which investigates the commercial potential of a putative MERS-CoV vaccine in all relevant target groups (preventative and emergency scenarios) to 2035. The potential of public (stockpile) and potential private markets are explored. There is comparative analysis of other **CEPI** based initiatives, e.g. Nipah and Lassa. Detailed case study analyses of other vaccine procurement/deployment scenarios also serve as guidance with all assumptions clearly outlined. A thorough review of current disease background/epidemiology and R&D competitive environment are also included. This product is ideally suited to organisations wishing to quantify the MERS-CoV vaccine opportunity.

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to MERS-CoV vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral based-pathogens, especially Ebola, Nipah and Lassa virus has also been utilised.

### PRODUCT CONTENTS:

Published January 2020 (CAT No: VAMV082)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

#### Contents – Summary presentation (.pdf)<sup>1</sup>

Contents

Author's notes

Executive summary

[SECTION 1] MERS-CoV vaccines: key commercial model outputs

[SECTION 2] MERS-CoV: introduction to the virus and disease background

[SECTION 3] MERS-CoV: disease epidemiology

[SECTION 4] MERS-CoV: vaccine research and development

[SECTION 5] MERS-CoV: clinical stage studies in vaccine development

[SECTION 6] MERS-CoV vaccines: modelling commercial potential

[SECTION 7] Case study analyses

Bibliography

About **VacZine Analytics**

Disclaimer

**PAGES: ~154 slides** fully referenced/sourced. Available in .pdf form

#### Contents – Vaccine demand model (MS Excel-based)

Worksheets = >30 interconnected

<sup>1</sup> Full contents i.e. title per slide is available upon request

**PRODUCT COST:**

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$8,995.00**/ GBP **£6995.00**\* (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to the final invoice total

# - indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary

**HOW TO ORDER:**

To order, please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and the “spiral logo” are UK Registered Trademarks, 2009

## BIBLIOGRAPHY

References – available upon request

Bringing life to vaccine strategy...

**[www.vaczine-analytics.com](http://www.vaczine-analytics.com)**

#### **TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €uro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

#### **VacZine Analytics**

A division of Assay Advantage Ltd  
Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 927049  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** ® and “the spiral logo” are UK Registered Trademarks, 2009